My Take, For What It's Worth: In light of today's announcement I cannot explain the price drop. I did not expect a big rise, but a few cents should have come our way. The lack of details might be the reason. But I don't think CYGX can give out pricing details at this point in time. It is clear to me that CYGX and ALdevron have developed a symbiotic relationship to some degree. Aldevron knows that they are no longer going to be able to supply fermented DNA as part of their business. Rather than compete in that arena, they are trying to help CYGX with the synDNA. Aldevron can still participate by providing their GIA vaccine testing capability. Aldevron has more contacts in this area of the industry. I think they are using their influence to get CYGX in the door, so to speak. CYGX is providing the testing quantities of synDNA plasmids. Aldevron is doing the effectiveness testing for the benefit of the unnamed 3rd party client. So far, Aldevron is upbeat about the effectiveness thus far shown by the CYGX plasmid. One of these days we will be told who the 3rd Party client is. If that client is a significant pharmaceutical/vaccine company....then we will see the stock price take off. I don't think the "sales" thus far will amount to any significant revenue. At best, CYGX is probably providing the testable quantities at cost. Which is OK. Anything to promote other companies into testing synDNA for their projects. Quality and pricing will sell synDNA in the final analysis. This looks to me like a great place to add more shares for anyone not fully invested.
